Important Announcement
PubHTML5 Scheduled Server Maintenance on (GMT) Sunday, June 26th, 2:00 am - 8:00 am.
PubHTML5 site will be inoperative during the times indicated!

Home Explore 2021 Virtual GPF Slides

2021 Virtual GPF Slides

Published by Health Technology Assessment International (HTAi), 2021-02-26 19:11:06

Description: 2021 Virtual GPF Slides

Search

Read the Text Version

Communication of uncertainty during the “output” phase-Group 6 • Define and communicate various types of uncertainty clinical/econ/other • Use/define appropriate tools for assessing specific types of uncertainties • HTA agencies should have framework process for communicating uncertainties

Plenary Discussion

Sli.do Poll Results

Wordcloud poll The 3 Most Important Changes to HTA 024 Consideration and Communication of Uncertainty in Your View How it could be resolved in a conditional reimbursement setting Transparency in evidence not considered and considered withsimple explanations Par t icipat ionCollaborative Transparent Meaningful specific and m eaningful Iterativity Respect Transparent HTA processes Di sag g r eg at i o n Ri g o u r o u s Consistently Im pact Transarency How TransparencyTimely Early discussion More cooperation global scores/weighting Tr ustCandid m ulti-stakeholdersEasy data transparency t o ler an ce early dialogue Diligent opportunities to resolve Multi-stakeholder engagement Disaggregate Separate out clinical from economic uncertainty

What’s Next? • Further collation and consolidation of thinking over 3 days • Development of IJTAHC manuscript and GPF panel at annual meeting • Forum evaluation, slides, and session recordings (next week) • Post-meeting report (10-14 days)

Topic Selection 2022 (n=51) 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 HTA 2030 HTA Management of RWE, Part 2 HTA Harmonization HTA in a Changing COVID-19 and HTA Disruptive Technologies Patient and Public Demographic Landscape Involvement in HTA Lifecycle

Topic Selection 2022 • Other suggestions: – Health and/or statistical literacy/numeracy – Methods and evidence for innovative technologies – HTA variation for same technology – Medical devices – Interaction between HTA and clinical guidelines – Judicialization and HTA – MCDA – Expansion of HTA beyond therapies that directly affect health

See you in den Hague!

Thank You 1-780-448-4881 | [email protected]| | htai.org Follow us on Twitter, Facebook, Linked In @HTAiorg


Like this book? You can publish your book online for free in a few minutes!
Create your own flipbook